Pembroke, Bermuda-based Covidien has begun trading on the New York and Bermuda Stock Exchanges, marking its debut as an independent diversified health care products company. The business, formerly known as Tyco Healthcare, recently spun off from Tyco International.
Company chief executive Richard Meelia said that "Covidien is distinguished by its outstanding portfolio of well-established and highly respected global brands that are leaders in several fast-growing product categories. As a premier provider of medical devices, supplies, imaging products and pharmaceuticals, we look forward to strengthening our longtime collaborative partnerships with medical professionals and institutions as we identify critical clinical needs and meet them with innovative, quality products." With industry-leading brand names that include Autosuture, Kendall, Mallinckrodt, Nellcor, Puritan Bennett, Syneture, US Surgical and Valleylab, Covidien products compete in five business segments: medical devices, imaging solutions, pharmaceutical products, medical supplies and retail products. In 2006, the firm saw revenues of $9.6 billion, with over one-third of its sales made outside the USA.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze